These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

199 related articles for article (PubMed ID: 9577052)

  • 1. Current role of chemotherapy protectors in cancer treatment.
    Cáceres W; Báez L; Aponte I; Rodríguez N; Maldonado A
    Bol Asoc Med P R; 1997; 89(10-12):184-8. PubMed ID: 9577052
    [TBL] [Abstract][Full Text] [Related]  

  • 2. American Society of Clinical Oncology clinical practice guidelines for the use of chemotherapy and radiotherapy protectants.
    Hensley ML; Schuchter LM; Lindley C; Meropol NJ; Cohen GI; Broder G; Gradishar WJ; Green DM; Langdon RJ; Mitchell RB; Negrin R; Szatrowski TP; Thigpen JT; Von Hoff D; Wasserman TH; Winer EP; Pfister DG
    J Clin Oncol; 1999 Oct; 17(10):3333-55. PubMed ID: 10506637
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Current role of protective agents in cancer treatment.
    Schuchter LM
    Oncology (Williston Park); 1997 Apr; 11(4):505-12, 515-6; discussion 517-8. PubMed ID: 9130273
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A randomized trial of amifostine in patients with high-dose VIC chemotherapy plus autologous blood stem cell transplantation.
    Hartmann JT; von Vangerow A; Fels LM; Knop S; Stolte H; Kanz L; Bokemeyer C
    Br J Cancer; 2001 Feb; 84(3):313-20. PubMed ID: 11161394
    [TBL] [Abstract][Full Text] [Related]  

  • 5. American Society of Clinical Oncology 2008 clinical practice guideline update: use of chemotherapy and radiation therapy protectants.
    Hensley ML; Hagerty KL; Kewalramani T; Green DM; Meropol NJ; Wasserman TH; Cohen GI; Emami B; Gradishar WJ; Mitchell RB; Thigpen JT; Trotti A; von Hoff D; Schuchter LM
    J Clin Oncol; 2009 Jan; 27(1):127-45. PubMed ID: 19018081
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Administration of the cytoprotectant amifostine.
    Lindemann K
    Clin J Oncol Nurs; 1998 Jul; 2(3):101-4. PubMed ID: 10232150
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Clinical use of Amifostine (WR-2721) as a preparation protecting healthy tissues from the cytotoxic effects of chemotherapy and radiation therapy].
    Wrembel-Wargocka J; Jabłońska H; Chomiczewski K
    Przegl Lek; 1996; 53(11):820-5. PubMed ID: 9173447
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cytoprotective agents used in the treatment of patients with cancer.
    Hogle WP
    Semin Oncol Nurs; 2007 Aug; 23(3):213-24. PubMed ID: 17693348
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Chemoprotectants: a review of their clinical pharmacology and therapeutic efficacy.
    Links M; Lewis C
    Drugs; 1999 Mar; 57(3):293-308. PubMed ID: 10193684
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Optimizing the management of chemotherapy-induced neutropenia.
    Dale DC
    Clin Adv Hematol Oncol; 2003 Nov; 1(11):679-84. PubMed ID: 16258470
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Prevention and treatment of the side effects of cancer chemotherapy].
    Iki S; Urabe A
    Gan To Kagaku Ryoho; 2000 Oct; 27(11):1635-40. PubMed ID: 11057312
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Chemoprotection in anticancer therapy: the emerging role of amifostine (WR-2721).
    Kurbacher CM; Mallmann PK
    Anticancer Res; 1998; 18(3C):2203-10. PubMed ID: 9703784
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Development of cancer chemotherapy. Cytoprotective agents].
    Lopez M
    Clin Ter; 2001; 152(2):135-43. PubMed ID: 11441524
    [No Abstract]   [Full Text] [Related]  

  • 14. Gastrointestinal toxicity of chemotherapeutic agents.
    Mitchell EP
    Semin Oncol; 2006 Feb; 33(1):106-20. PubMed ID: 16473649
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prevention and management of prostate cancer chemotherapy complications.
    Beer TM; Bubalo JS
    Urol Clin North Am; 2004 May; 31(2):367-78. PubMed ID: 15123414
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Hematopoietic growth factors in cancer chemotherapy.
    Crawford J; Foote M; Morstyn G
    Cancer Chemother Biol Response Modif; 1999; 18():250-67. PubMed ID: 10800487
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Approaches to managing carboplatin-induced thrombocytopenia: focus on the role of amifostine.
    Budd GT; Ganapathi R; Wood L; Snyder J; McLain D; Bukowski RM
    Semin Oncol; 1999 Apr; 26(2 Suppl 7):41-50. PubMed ID: 10348260
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Amifostine (ethyol) in the adjunctive treatment of children with acute lymphoblastic leukemia].
    Matysiak M; Stańczak E; Wójtowicz A
    Wiad Lek; 1998; 51 Suppl 4():210-4. PubMed ID: 10731970
    [TBL] [Abstract][Full Text] [Related]  

  • 19. 2002 update of recommendations for the use of chemotherapy and radiotherapy protectants: clinical practice guidelines of the American Society of Clinical Oncology.
    Schuchter LM; Hensley ML; Meropol NJ; Winer EP;
    J Clin Oncol; 2002 Jun; 20(12):2895-903. PubMed ID: 12065567
    [No Abstract]   [Full Text] [Related]  

  • 20. [Cardiac toxicity in cancer therapy].
    Łacko A; Włodarska I; Zymliński R; Mazur G; Wróbel T; Gisterek I
    Pol Merkur Lekarski; 2002 Jul; 13(73):79-85. PubMed ID: 12362515
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.